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Abstract 
OBJECTIVE–Islet-reactive CD8+ T-cells play a key role in the pathogenesis of type 1 
diabetes (T1D) in the NOD mouse. The predominant T-cell specificities change over 
time, but whether similar shifts also occur after clinical diagnosis and insulin 
treatment in T1D patients is unknown. 
RESEARCH DESIGN AND METHODS–We took advantage of a recently validated 
islet-specific CD8+ T-cell IFN-γ enzyme-linked immunospot (ISL8Spot) assay to 
follow responses against preproinsulin (PPI), GAD, IA-2 and islet-specific glucose-6-
phosphatase catalytic subunit-related protein (IGRP) epitopes in 15 HLA-A2+ adult 
T1D patients close to diagnosis and at a second time point 7-16 months after.  
RESULTS–CD8+ T-cell reactivities were less frequent at follow-up, as 28.6% of 
responses tested positive at T1D diagnosis vs. 13.2% after a median of 11 months 
(P=0.003). While GAD and IA-2 autoantibody (aAb) titers were unchanged in 75% of 
cases, the fraction of patients responding to PPI and/or GAD epitopes by ISL8Spot 
decreased from 60-67% to 20% (P<0.02). The previously subdominant IA-2206-214 and 
IGRP265-273 peptides were newly targeted, thus becoming the immunodominant 
epitopes. 
CONCLUSIONS–Shifts both in frequency and in immunodominance of CD8+ T-cell 
responses occur rapidly, as compared to slower changes in aAb titers. These different 
kinetics may suggest complementary clinical applications for T cell and aAb 
measurements. 
 
 
 
Abstract count: 206 words 
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CD8+ T-cells have recently emerged as crucial actors in the pathogenesis of type 1 
diabetes (T1D) in the NOD mouse (1,2). Three different CD8+ pathogenic clones 
specific for proinsulin (PI)B15-23 (3), islet-specific glucose-6-phosphatase catalytic 
subunit-related protein (IGRP)206-214 (4) and dystrophia myotonica kinase (DMK)138-
146 (5) have been described. These specificities are highly immunodominant in NOD 
mice, as T-cells recognizing them are abundantly present in the early insulitis 
infiltrates (6,7). Moreover, the rise in circulating IGRP206-214-specific CD8+ T-cells 
can predict impending T1D onset in NOD mice (8). 
 
More recent data suggest that there could be a hierarchy of spreading from one 
reactivity to another, as NOD mice made tolerant to PI are protected from diabetes 
and do not develop IGRP-specific CD8+ responses, while IGRP-tolerant mice still 
become diabetic and mount PI-specific responses (9). The initiating role of PI is 
further supported by the fact that PI knockout mice reconstituted with a hormonally 
active PI transgene carrying a single tyrosine to alanine mutation at position B16 are 
completely protected from T1D (10,11). This substitution affects both the PIB15-23 
epitope and an overlapping immunodominant PIB9-23 CD4+ epitope (12,13). 
 
Mirroring these mouse data, CD8+ T-cells have recently received increasing attention 
also for human T1D (14-19), as their detection could provide new autoimmune 
markers of β-cell aggression. Development of such markers is important to 
complement autoantibody (aAb) readouts. Indeed, aAbs can separate T1D from 
healthy subjects with high sensitivity and specificity, making them indispensable tools 
for diagnostic classification and T1D prediction. However, the utility of aAbs for 
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immune monitoring purposes is limited by the fact that they do not reflect tolerance 
restoration following therapeutic manipulation (20,21). 
 
To be clinically applicable, T-cell assays should be developed that can be easily 
transferred into routine laboratory testing. The first validation step for such assays is 
to test their diagnostic sensitivity and specificity in separating T1D from healthy 
subjects. For CD4+ T-cells, the cellular immunoblotting technique of Brook-Worrell 
et al. (22) was the assay showing the best performance (23). In many other instances, 
β-cell-specific CD4+ T-cells were detected in all individuals irrespective of disease 
status (24,25), although probably characterized by different phenotypes (26-28). 
 
For CD8+ T-cells, we have recently proposed an islet-specific CD8+ T-cell IFN-γ 
ELISpot (ISL8Spot) assay (18,29). The ISL8Spot employs HLA-A2-restricted β-cell 
epitopes derived from pre-PI (PPI) (30), GAD, insulinoma-associated protein 2 (IA-2) 
(17) and IGRP (31), which have been mostly identified by proteasome digestion and 
DNA immunization strategies (32). Using a single IFN-γ secretion readout on 
unfractionated PBMCs, this assay detects and quantifies β-cell-reactive CD8+ T-cells 
directly ex vivo (18). Beta-cell epitope-specific CD8+ T-cells were thus found at an 
average frequency of 0.008%, ranging from 0.0008 to 0.08% of total PBMCs. The 
presence vs. absence of these cells allowed discrimination of T1D vs. healthy subjects 
with high sensitivity and specificity (18).  
 
The natural history of CD8+ T-cell responses after T1D clinical onset and start of 
insulin treatment has not been explored. We know from the NOD mouse that the 
PIB15-23-specific fraction is highly immunodominant already at 5 wk (i.e., in the pre-
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diabetic period), but rapidly disappears, becoming negligible by 20 wk (i.e., after T1D 
onset). In parallel, the IGRP206-214-specific fraction increases in number, while 
undergoing an avidity maturation process which selects the clonotypes of higher 
avidity (6,8). Whether similar shifts in epitope targeting also apply to human T1D is 
unknown. We therefore used the ISL8Spot assay to measure CD8+ T-cell responses 
against different β-cell epitopes at T1D clinical onset and after some months of 
follow-up. Our results reveal a fast waning of most ISL8Spot responses, which 
contrasts with the steady titers of GAD and IA-2 aAbs. Few new T-cell reactivities 
appear, which focus on previously subdominant IA-2 and IGRP epitopes.    
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Research design and methods 
Peptides. The HLA-A2-restricted β-cell epitopes used (Tab. 1) were previously 
described (17,18,31). A viral peptide pool of Flu MP58-66 (GILGFVFTL), Epstein-
Barr virus BMLF280-288 (GLCTLVAML) and cytomegalovirus pp65495-503 
(NLVPMVATV) and phytohemagglutinin (PHA, 1 µg/ml; Sigma, Lyon, France) 
were used as positive controls. HIV gag77-85 (SLYNTVATL) and DMSO diluent were 
included as negative controls. All peptides were used at 10 µM and were >80% pure 
(Schafer-N, Copenhagen, Denmark). Responses against these 9- to 10-amino acid-
long epitopes originate from CD8+ T-cells, as previously shown (18). 
 
Study subjects. HLA-A2+ new-onset adult (>16 yr-old) T1D patients with acute 
onset of symptoms requiring permanent insulin treatment from the time of diagnosis 
(33) were recruited from the Diabetes Registry of the Province of Turin, Italy and 
from the GOFEDI Network, France (see Appendix for the detailed list of participating 
centers). All patients had metabolically controlled disease and were free of recent (<2 
weeks) infectious or inflammatory conditions at the time of blood draw. Parallel 
recruitment of Caucasian healthy control subjects took place at the same Institutions. 
Available subjects wishing to continue the study were subsequently drawn and tested 
a second time under identical conditions. All subjects gave informed consent and the 
study was approved by the relevant Ethics Committees. 
 
Blood processing. All blood samples were shipped overnight at room temperature. 
Rapid HLA-A2 screening was performed with the BB7.2 mAb, followed by 
subtyping using the Olerup SSP HLA*02 kit (GenoVision/Qiagen, Vienna, Austria) 
to verify the presence of the HLA-A*0201 allele (>95% of HLA-A2+ individuals). 
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PBMCs were isolated by density gradient centrifugation using lymphocyte separation 
medium (PAA, Les Mureaux, France), and immediately used or stored frozen (10% 
DMSO in pooled human male AB serum). The second testing was performed under 
the same condition (i.e., fresh or frozen PBMCs) of the first testing.  
 
Islet Abs. Serum GAD, IA-2 and insulin (a)Abs were measured by radioligand 
binding assays, following protocols previously evaluated within the Diabetes 
Antibody Standardization Program (DASP; Lab no. 137) (34). Sensitivities in the 
2005 DASP were 84% for anti-GAD, 76% for anti-IA-2 and 28% for anti-insulin 
(IAA), where the specificity was set at 95%. Changes >33% between two aAb titer 
determinations were considered significant.  
 
ISL8Spot assay. Ninety-six well PVDF plates (Millipore, Saint-Quentin-en-Yvelines, 
France) were coated overnight with an anti-IFN-γ Ab (U-CyTech, Utrecht, The 
Netherlands). Plates were subsequently blocked with RPMI + 10% human serum 
(PAA) and peptides added (10 µM final concentration) in triplicate wells along with 
recombinant human IL-2 (0.5 U/ml; R&D Systems, Lille, France), as previously 
reported (18). PBMCs were seeded at 3x105 cells/well and cultured for 20-24 h. 
Following PBMC removal, IFN-γ secretion was visualized with a biotin-conjugated 
anti-IFN-γ Ab (U-CyTech), alkaline phosphatase-conjugated ExtrAvidin and 
Sigmafast  5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) 
tablets (both from Sigma). Spots were counted using an AID reader (Strassberg, 
Germany) and means of triplicate wells calculated. All ISL8Spot readouts are 
expressed as spot-forming cells (SFC)/106 PBMCs. 
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The cut-off for a positive response was set at 3SD above the average basal reactivity 
(i.e., reactivity against HIV gag77-85 and DMSO diluent alone). This was chosen as the 
cut-off allowing for the best diagnostic sensitivity (i.e., highest number of positive 
responses to β-cell epitopes in T1D patients) and specificity (i.e., lowest number of 
positive responses in healthy controls), as determined by receiver-operator 
characteristics analysis (18).  
 
T-cell clone dilution experiments. A Flu MP58-66-specific HLA-A2-restricted T-cell 
clone was serially diluted into PBMCs from 3 different HLA-A2+ donors showing no 
response to the MP58-66 peptide and displaying different levels of basal reactivity in 
the absence of stimuli. These cell mixtures were challenged in the presence of 10 µM 
Flu MP58-66 peptide using the same ELISpot format as above.  
 
Statistical analysis. Values are expressed as mean ±SD or median (range), according 
to their distribution. Comparisons between proportions were made with the χ2 test and 
Fisher's exact test, when appropriate. Comparisons of means between two groups 
were carried out with the Student's t test for normal distributed variances or with the 
Mann-Whitney U test for non-normal variances. P<0.05 was considered to be of 
statistical significance. 
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Results  
Assay validation 
The reproducibility of our ELISpot technique has been previously reported (18). 
Variability was found to be of 14.1% intra-assay, 4.2% at the analytical inter-assay 
level (i.e., using thawed PBMC samples frozen on the same occasion) and 9.2% at the 
pre-analytical and analytical level (i.e., using separate blood draws from the same 
donor). One further problem that is encountered in a longitudinal setting is that the 
basal reactivity level (i.e., spontaneous IFN-γ production in the absence of stimuli) 
can be different not only among different subjects, but also within the same individual 
when analyzed at different time points. To address whether these variations could 
affect the detection sensitivity of the technique, we took HLA-A2+ healthy donors 
displaying different IFN-γ background levels that demonstrated no response to the Flu 
MP58-66 epitope, mixed their PBMCs with serially diluted numbers of a Flu MP58-66-
specific clone, and tested these mixtures in ELISpot against the MP58-66 peptide. As 
shown in Figure 1, background levels more than 10-fold different (7.3, 21.7 and 85.5 
SFC/106 PBMCs, respectively) did not significantly affect the detection sensitivity of 
the system (i.e., the basal-subtracted net signal) over a wide range of frequencies. 
Moreover, all counts were above the basal + 3SD positive cut-off value calculated 
from the respective backgrounds.      
 
Most CD8+ T-cell responses are short-lived after T1D onset 
We considered β-cell epitopes that we previously defined as targets of CD8+ T-cells 
in 19-50% of adult new-onset T1D patients, but not of age-matched healthy controls 
(17,18). These epitopes were derived from four different β-cell Ags, namely PPI, 
GAD, IA-2 and IGRP. A complete list is presented in Table 1. 
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Fifteen new-onset T1D patients were available for follow-up within a median of 11 
months (range 7-16; Tab. 2). Their mean age at diagnosis was of 27.6±8.4 years and 
their median T1D duration at the time of the first blood draw was of 13 days (range 2-
180). Fifteen age-matched healthy controls (mean age 28.8±5.9) were also tested 
twice, within a median follow-up period of 14 months (range 12-26). 
Results expressed as number of SFC/106 PBMCs, are summarized in Figure 2. All 
healthy control subjects were negative at follow-up, including two individuals (i.e., 
H08 and H09) previously found to be weakly positive for 1-2 epitopes. The number of 
T1D patients positive for T-cell responses dropped from 80% (12/15) at diagnosis to 
53% (8/15) during follow-up (P=0.12). Moreover, while positive patients at the time 
of diagnosis recognized multiple epitopes (median reactivities/patient = 2, range 0-6), 
there were mostly single reactivities that persisted during follow-up (median 1, range 
0-3; P=0.05). Overall, the number of positive responses out of the total tested 
decreased from 28.6% (34/119) to 13.2% (16/121; P=0.003). 
Those patients with detectable reactivities could be divided in two categories: on one 
side, patients already positive at diagnosis (i.e., patients P04, P09, P10, P11, P14 and 
P15), in whom at least one of the original epitopes was still recognized, while new 
ones sometimes emerged (i.e., P04, P11, P14). On the other side, patients whose 
responses were all negative at diagnosis and who developed scattered reactivities at 
follow-up (1-2 epitopes recognized; patients P06 and P08). CD8+ T-cell responses 
against a pool of viral epitopes were included as internal controls. They decreased or 
disappeared only in 2 patients (P08 and P11), remaining unchanged in all other 
instances (13/15; 87%).  
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CD8+ T-cell responses shift towards IA-2206-214 and IGRP265-273 epitopes after 
T1D onset   
A simplified graphical representation of these data is provided in Figure 3, where only 
CD8+ T-cell responses testing positive either at diagnosis or follow-up are 
represented. Such responses are displayed as absent (<3SD above the mean basal 
reactivity), low (3-4SD), intermediate (4-5SD) or high (>5SD), following the 
quantitative ranking reported in Figure 2. 
Of the total positive T-cell responses to islet epitopes observed at diagnosis, the 
majority (26/42; 62%) dropped to non-detectable levels, while few of them (8/42; 
19%) remained detectable at follow-up. Only in 5 patients (i.e., P04, P06, P08, P11 
and P14) did new epitopes become targeted (8/42; 19%). Except for patient P04 who 
recognized PIB18-27, in all other instances (7/8; 87.5%) the newly targeted epitopes 
were IA-2206-214 and IGRP265-273. These two epitopes were recognized together in 3 of 
4 patients. 
While the number of patients responding to epitopes derived from PPI and GAD 
significantly decreased (60% to 20% for PPI; 67% to 20% for GAD; P<0.02; Fig. 
4A), IA-2206-214 became the major immunodominant epitope detected at follow-up. 
This was true both in terms of IA-2206-214-responding patients (5/14, 36%; Fig. 4B) 
and of frequency of IA-2206-214 among all targeted epitopes (5/16, 31%; Fig. 5). 
Second in order came IGRP265-273, which was recognized by 27% (3/11) of patients 
(Fig. 4B), thus constituting 19% (3/16) of all reactivities detected (Fig. 5). Another 
20% of patients and 19% of reactivities were covered at follow-up by GAD114-123 and 
PIB18-27, which were the two immunodominant epitopes at diagnosis (53% and 36% 
prevalence and 23% and 14% relative frequency, respectively). Thus, 4 epitopes (i.e., 
the newly immunodominant IA-2206-214 and IGRP265-273, along with GAD114-123 and 
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PIB18-27) accounted for 88% of all reactivities detected at follow-up. Three epitopes 
(PIB10-18, GAD536-545 and IGRP228-236) were instead no longer recognized. This 
focusing of T-cell responses towards more selected epitopes contrasted with the 
situation at diagnosis (Fig. 4B and Fig. 5) where, besides GAD114-123 and PIB18-27 
emerging as the immunodominant specificities, the other 7 epitopes were evenly 
ranked (13-29% prevalence, 6-12% of total reactivities).  
 
aAb titers remain stable in face of fading CD8+ T-cell responses.  
A sharp dichotomy was observed when comparing the progression of aAb titers and 
T-cell responses (Tab. 2). While the fraction of positive ISL8Spot responses 
decreased from 28.6% to 13.2% (P=0.003), that of positive GAD or IA-2 aAb 
responses did not change (63.3% vs. 60.7%; P=0.83). Even the titers of GAD and IA-
2 aAbs remained nearly identical in the majority of cases (21/28; 75.0%). A decrease 
in titers was registered only in 17.9% (5/28) of cases, while both GAD and IA-2 
further rose only in one patient. 
The picture was different when we compared (a)Ab and T-cell responses against PPI. 
In line with their adult onset T1D, all but two (13/15; 86.7%) patients were negative 
for IAA at diagnosis (Tab. 2). Following initiation of insulin therapy, insulin Ab titers 
became positive in most patients, with the exception of P03 and P10. P10 was also 
one of the three patients for whom PI-specific T-cell responses were still detectable at 
follow-up. 
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Discussion 
We here describe the progression of β-cell-directed CD8+ T-cell responses after T1D 
clinical onset and initiation of insulin therapy. As the aim of this study was the 
longitudinal evaluation of T1D patients rather than their comparison with healthy 
controls, the fact that these two groups were matched only with respect to age does 
not bias our conclusions. In this longitudinal setting, it is instead essential to 
distinguish between changes in T-cell responses due to the variability of the ISL8Spot 
technique from those reflecting true biological fluctuations. In this respect, the 9.2% 
inter-assay variability registered when analyzing separate blood draws from the same 
individual (18) is reassuring. Although some fluctuations in the ELISpot background 
noise are unavoidable, most of these fluctuations were shown to have a minimal 
impact on the final basal-subtracted signal obtained (18). Moreover, detection of a 
serially diluted clone over different basal backgrounds was also similar. Three main 
conclusions can thus be drawn: i) most CD8+ T-cell responses are short-lived after 
clinical onset; ii) some new reactivities appear, which preferentially target the 
previously subdominant IA-2206-214 and IGRP265-273 epitopes; iii) GAD and IA-2 aAb 
titers display less fluctuations.   
 
There are several hypotheses which, without being mutually exclusive, could explain 
the rapid disappearance of most β-cell specific IFN-γ-producing CD8+ T-cells after 
T1D diagnosis. The simplest explanation is that these T-cells are no longer detected 
just because they are no longer present at sufficient frequencies. They may have been 
deleted or suppressed as part of the natural blunting of (auto)immune responses. 
Although some β-cells are thought to survive for a long time after T1D onset, the 
increasing paucity of islet Ags may doom most of these T-cells to die for lack of Ag 
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stimulation. These cells may also become undetectable because of a change in their 
recirculation or homing behavior. Alternatively, β-cell-specific T-cells may have 
stopped secreting IFN-γ, changing their phenotype to a different one. There are indeed 
examples in the setting of both chronic virus infections (35) and of neoplastic diseases 
(36), where activated virus- or tumor-specific CD8+ T-cells persist, but lose their 
effector function (i.e., cytotoxicity and cytokine production).    
 
A third explanation is that the epitope specificity of the CD8+ T-cell population may 
have shifted towards different targets. Although it is possible that other unknown 
specificities become prevalent, an epitope focusing phenomenon was observed. 
Indeed, only six of the nine original epitopes were still targeted at follow-up. 
Furthermore, a shift in the epitopes preferentially targeted by CD8+ T-cells was 
observed, as two previously subdominant IA-2 and IGRP epitopes became targeted by 
27-36% of patients, while the previously immunodominant responses against PI and 
GAD epitopes became less prominent. IA-2206-214 and IGRP265-273 (but not IGRP228-
236) were also the two epitopes newly targeted in the vast majority (87.5%) of cases. 
These results are relevant in light of the recent debate as to whether there is a 
hierarchy of epitope spreading in the T1D pathogenic process. Data in the NOD 
mouse suggest that PI may stand at the source of this spreading (10,11), while IGRP 
would lie downstream in the cascade (9). Our human data is consistent with this 
model. Indeed, PI- and GAD-specific responses decreased, while IA-2206-214-specific 
and – to a lesser extent – IGRP265-273-specific T-cells became immunodominant. 
While the decreasing PI-specific responses and the increasing of IGRP265-273 reactivity 
are reminiscent of NOD mouse data (6), the finding of a similar phenomenon for 
GAD and IA-2 is unparalleled. This is not surprising, since GAD and IA-2 are 
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thought to be important target Ags in human T1D (15,17,26,37-39), but not in the 
NOD mouse (40-43). Consideration of additional epitopes poorly recognized at T1D 
onset (17,18) may reveal further specificities becoming immunodominant at later time 
points. It is also interesting that, similarly to the overlapping PIB9-23 and PIB15-23 
mouse epitopes, the immunodominant human CD8+ T-cell epitopes at diagnosis (i.e., 
GAD114-123) and at follow-up (i.e., IA-2206-214) overlap with the DR4-restricted 
epitopes GAD115-127 (44,45) and IA-2206-221 (46).   
The observed shift in epitope specificity could be due either to the emergence of novel 
clonotypes or to an avidity maturation of pre-existing ones. Indeed, if IA-2206-214-
specific CD8+ T-cells undergo avidity maturation, this would lower the ISL8Spot 
detection threshold and thus increase their measured frequencies. Alternatively, the 
measured frequencies could increase due to higher precursor numbers following de 
novo generation and/or expansion. The study of epitope-specific CD8+ clones 
obtained at different time points will clarify this issue. 
 
Another important question is whether the observed changes in CD8+ T-cell responses 
are part of the T1D natural history, or rather reflect an immunological effect induced 
by insulin therapy. Indeed, daily insulin treatment in these patients may have 
modulated T-cell responses. Consistent with this hypothesis, PI-specific responses 
were frequently undetected at follow-up (12 of 15 patients; 80%), a trend which 
contrasted with the opposite behavior of insulin Ab responses, which rose in most 
(10/12; 83%) instances. The increase in insulin Ab titers could also contribute to this 
shift in T-cell responses, as Abs could change the efficiency of presentation of PI-
derived T-cell epitopes (47,48). Besides the possibility of a direct effect of PI as an 
Ag on its cognate T-cells, an indirect tolerogenic effect could also be mediated by the 
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hormonal activity of PI. Insulin treatment can indeed reduce the functional pressure 
on the β-cell, which may translate in reduced β-cell apoptosis and/or reduced β-cell 
Ag release. 
 
The slower changes observed for aAb titers as compared to T-cell responses have 
important implications. Autoreactive memory B-cells are long-lived, and can keep 
replenishing the plasma cell compartment without further need for Ag-specific 
stimulation (49). It is not completely clear whether the same rules apply to CD8+ T-
cell memory (50). The efficient B-cell homeostasis may make it possible for the aAb 
titers to be maintained longer than T-cell responses. The faster dynamics of CD8+ T-
cell responses could make their measurement more suitable to promptly reflect the 
autoimmune modifications of the disease. In this scenario, aAb and T-cell 
measurements could find complementary clinical applications. We hypothesize that 
the slow changes of aAb titers may make them more suitable for predicting the “ifs” 
of T1D (i.e., 5-year probability to develop disease in at-risk subjects). Conversely, the 
faster kinetics of T-cell responses may be less useful to predict long-term odds, but 
better suited to reflect more proximal events, i.e., the “whens” of T1D once disease 
onset, remission or relapse are approaching.   
 
Another important application for T-cell assays will be for the etiologic classification 
of borderline cases. One such example is patient P03, whose diagnosis of T1D could 
be questioned, having ketoacidosis and insulin-dependency at diagnosis but being 
seronegative and genetically protected (DR15+ with no HLA Class II susceptibility 
allele). Nonetheless, his robust CD8+ T-cell responses at diagnosis hint an 
autoimmune component for his diabetes. 
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The disappearance of most CD8+ T-cell responses following T1D onset and initiation 
of insulin therapy has also important implications for the application of T-cell assays 
in the clinics. There is quite some parallelism between human and NOD mouse data, 
as in both cases T-cell responses significantly wane after clinical onset (8). If this 
human/mouse parallel holds true also for the pre-diabetic period, we may find the 
zenith of T-cell responses before diabetes onset. Longitudinal follow-up of at-risk 
subjects will shed further light on the time course of these events. 
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Tables 
 
Table 1. The HLA-A2-restricted β-cell epitope panel used in the ISL8Spot assay. 
 
Name Sequence 
PPI2-10 ALWMRLLPL 
PIB10-18 (PPI34-42) HLVEALYLV 
PIB18-27 (PPI42-51) VCGERGFFYT 
PIA12-20 (PPI101-109) SLYQLENYC 
 
GAD65114-123 VMNILLQYVV 
GAD65536-545 RMMEYGTTMV 
  
IA-2206-214 VIVMLTPLV 
  
IGRP228-236 LNIDLLWSV 
IGRP265-273 VLFGLGFAI 
 
For PPI, aa numbering is given both with respect to the PI sequence alone (aa B1-A21) and 
to the complete PPI sequence (aa 1-110).  
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Table 2. Characteristics of HLA-A2+ new-onset T1D patients and age-matched healthy controls. 
 
  
 
The 97.5th percentile cut-off values for Ab titers are as follows: GAD Abs: 180 arbitrary units 
(AU). IA-2 Ab: 80 AU. IAA: 0.7 AU. Positive Ab titers are displayed in bold, while changes in 
titers >33% are shaded in grey. –, not determined. 
 
T1D patients (n=15)
Case Age at T1D duration Follow-up HLA
no. 1st draw at diagnosis time DRB1
(yr) (days) (months) 1st 2nd 1st 2nd 1st 2nd
P01 38 M 180 13 04-16 2,817 2,384 13 21 2.54 4.43
P02 37 M 60 11 07-08 2,898 1,118 30 16 0.24 0.89
P03 43 M 5 11 11-15 60 61 11 18 0.30 0.45
P04 21 F 24 16 03-16 2,894 2,044 598 244 0.40 1.36
P05 23 M 16 7 04-13 58 - 18 - 0.31 21.7
P06 33 M 19 14 - 2,114 5,102 505 1,204 0.44 1.99
P07 16 F 6 7 01-01 1,441 1,413 578 315 0.29 2.30
P08 18 M 13 14 03-15 883 722 11 35 0.35 9.30
P09 29 M 26 12 03-04 2,548 2,572 1,570 1,334 0.35 2.10
P10 27 M 70 14 03-13 3,292 3,105 30 22 0.77 0.43
P11 24 F 4 7 03-13 1,602 88 2,876 3,688 0.33 11.4
P12 40 M 5 8 04-07 298 273 20 19 0.62 3.47
P13 18 F 2 8 01-04 2,352 2,105 5,542 5,255 0.40 3.84
P14 22 M 11 8 01-03 190 125 21 14 0.33 3.25
P15 25 M 6 7 04-11 114 87 3,638 1,872 0.58 3.05
Healthy subjects (n=15)
H01 25 F 24 13-14 - 40 - 19 - 0.23
H02 26 F 16 09-11 - 37 - 11 - 0.20
H03 30 F 26 01-16 - 41 - 15 - 0.37
H04 32 M 15 11-16 - 60 - 10 - 0.22
H05 33 F 15 04-14 - 63 - 9 - 0.23
H06 27 M 14 07-15 - 25 - 16 - 0.26
H07 26 F 22 08-11 - 43 - 13 - 0.47
H08 25 F 22 11-15 - 48 - 14 - 0.36
H09 23 F 12 03-11 - 41 - 26 - 0.76
H10 27 M 14 01-11 - 66 - 28 - 0.20
H11 26 F 14 01-07 - 43 - 27 - 0.28
H12 26 F 14 13-15 - 70 - 14 - 0.15
H13 25 M 14 - - 76 - 20 - 0.28
H14 48 F 14 04-11 - 70 - 13 - 0.13
H15 33 M 13 07-13 - 60 - 14 - 0.49
Insulin Ab
(AU)Sex
GAD Ab
(AU)
IA-2 Ab
(AU)
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Figure Legends 
 
Figure 1. ELISpot detection of epitope-specific signals over different background noise 
levels. Flu MP58-66-specific T-cells were serially diluted into PBMCs displaying different 
background noise values, as indicated. The number of MP58-66-specific T cells plated is 
shown on the X axis, while the Y axis displays the SFC counted per well after basal 
background subtraction. All counts were above the basal + 3SD cutoff value for a positive 
response, as calculated from the respective background noise levels. A representative 
experiment out of two performed is shown.     
 
Figure 2. Summary of HLA-A2+ T1D patients (n = 15) and healthy control subjects (n = 15) 
assayed for β-cell reactivities by ISL8Spot close to diagnosis (0 mo) and at follow-up (7-14 
mo, as indicated). All values, including basal + n SD cutoffs, are expressed as SFC/106 
PBMCs and are basal subtracted. Unsubtracted basal values (reactivities to DMSO and gag77–
85) are shown in the last row of each column. Reactivities are ranked as low (between 3 and 4 
SD, in yellow), intermediate (between 4 and 5 SD, in orange), and high (more than 5 SD, in 
red). ++++, off-scale ELISpot reading. 
 
Figure 3. Longitudinal follow-up of ISL8Spot responses against β-cell epitopes in T1D 
patients. Patients previously tested by ISL8Spot close to diagnosis (Fig. 2; 0 mo here) were 
re-assayed after 7-14 mo follow-up, as indicated. Reactivities testing positive at either time 
point are depicted and ranked as absent (<3SD above basal), low (3-4SD), medium (4-5SD) 
and high (>5SD) as in Fig. 2. Responses against a pool of viral epitopes are included as 
positive controls.  
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Figure 4. (A) Cumulative prevalence of CD8+ T-cell responses against epitopes derived from 
PPI, GAD, IA-2 and IGRP in T1D patients at diagnosis and at follow-up. *P<0.02. (B) 
Prevalence of single epitope specificities in T1D patients at diagnosis and at follow-up. 
**P<0.05.   
 
Figure 5. Relative distribution of epitope specificities. The percent prevalence of each 
epitope out of all epitopes recognized at diagnosis (n=34) and at follow-up (n=16) is shown.  
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